



ABN 64 068 943 662 F6A / 1-15 Barr Street Balmain NSW 2041 Australia

> Tel: +61 (0) 2 9555 6986 Email: info@benitec.com

> > www.benitec.com

## BENITEC CEO PRESENTATION AT EUROPEAN BIOTECH CONFERENCE

**Brussels, Belgium, 20 May 2014:** Benitec Biopharma Limited (ASX:BLT) is pleased to advise that Managing Director and CEO, Dr Peter French will deliver a presentation by invitation at the *Pharmaceutical & Biotech Finance Leaders Forum*, held in Brussels on 20 May at 2.50pm local time. The topic of the presentation will be "Managing a global pipeline in a virtual biotech company".

Dr French's presentation will cover:

- How to identify and contract with potential collaboration partners.
- Different types of deal structures to maximise limited finances whilst advancing the pipeline.
- Managing global partners to keep the programs on track.
- Leveraging partnerships to identify additional sources of funding.

A copy of the presentation is attached.

The conference will be attended by representatives from a number of pharmaceutical companies as well as smaller biotech companies and investors. For more information, please contact the persons below or visit the Company's website at www.benitec.com.

Company	Investor relations
Carl Stubbings	Jane Lowe
Chief Business Officer	Buchan Consulting
Tel: +61 (2) 9555 6986	Tel: +61 (2) 9237 2807
Email: cstubbings@benitec.com	Email: jlowe@buchanwe.com.au

## About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and lifethreatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at <a href="https://www.benitec.com">www.benitec.com</a>.